المؤلفون: Sheehy J; Cancer Care Services, Royal Brisbane and Women's Hospital, Queensland, Brisbane, Australia.; School of Medicine, University of Queensland, Brisbane, Australia.; Cancer Research Program, QIMR Berghofer Medical Research Institute, Queensland, Brisbane, Australia., Lane SW; Cancer Care Services, Royal Brisbane and Women's Hospital, Queensland, Brisbane, Australia.; School of Medicine, University of Queensland, Brisbane, Australia.; Cancer Research Program, QIMR Berghofer Medical Research Institute, Queensland, Brisbane, Australia.

المصدر: Blood advances [Blood Adv] 2024 Apr 23; Vol. 8 (8), pp. 2018-2019.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Azacitidine*/*analogs & derivatives, Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/mortality , Azacitidine*/therapeutic use, Humans ; Male ; Antimetabolites, Antineoplastic/therapeutic use ; Antimetabolites, Antineoplastic/pharmacology ; Female ; Middle Aged ; Aged

المؤلفون: Roboz GJ; Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine and the New York-Presbyterian Hospital, New York, NY., Sanz G; Hospital Universitari i Politècnic La Fe, Instituto de Investigación Sanitaria La Fe,Valencia, and CIBERONC Cáncer, Instituto de Salud Carlos III, Madrid, Spain., Griffiths EA; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Yee K; Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Récher C; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Byrne MT; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Patkowska E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Kim HJ; Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Thomas X; Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France., Moors I; Department of Hematology, Universitair Ziekenhuis Gent, Ghent, Belgium., Stock W; Department of Medicine, The University of Chicago Medical Center, Chicago, IL., Illés Á; Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Fenaux P; Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris and Université Paris Cité, Paris, France., Miyazaki Y; Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan., Yamauchi T; Department of Hematology, University of Fukui Hospital, Eiheiji-chō, Japan., O'Connell CL; Keck School of Medicine of USC, Los Angeles, CA., Hao Y; Astex Pharmaceuticals, Inc, Pleasanton, CA., Keer HN; Astex Pharmaceuticals, Inc, Pleasanton, CA., Azab M; Astex Pharmaceuticals, Inc, Pleasanton, CA., Döhner H; Department of Internal Medicine, Ulm University Hospital, Ulm, Germany.

المصدر: Blood advances [Blood Adv] 2024 Apr 23; Vol. 8 (8), pp. 2020-2029.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Clinical Trial, Phase III; Multicenter Study

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Azacitidine*/*analogs & derivatives, Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/mortality , Azacitidine*/therapeutic use, Humans ; Female ; Middle Aged ; Male ; Aged ; Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Recurrence ; Treatment Outcome ; Cytarabine/therapeutic use ; Aged, 80 and over ; Young Adult ; Drug Resistance, Neoplasm

المؤلفون: Miklos E; Department of Hematology, Somogy County Móritz Kaposi General Hospital, Kaposvar, Hungary., Oliver TP; Department of Hematology, Somogy County Móritz Kaposi General Hospital, Kaposvar, Hungary., Adam K; Department of Hematology, Somogy County Móritz Kaposi General Hospital, Kaposvar, Hungary., Eva K; Department of Hematology, Somogy County Móritz Kaposi General Hospital, Kaposvar, Hungary., Balazs K; Department of Hematology, Somogy County Móritz Kaposi General Hospital, Kaposvar, Hungary., Eszter K; Department of Hematology, Somogy County Móritz Kaposi General Hospital, Kaposvar, Hungary., Anett P; Department of Hematology, Somogy County Móritz Kaposi General Hospital, Kaposvar, Hungary., Viktoria GK; Department of Hematology, Somogy County Móritz Kaposi General Hospital, Kaposvar, Hungary., Jozsef H; Department of Hematology, Somogy County Móritz Kaposi General Hospital, Kaposvar, Hungary., Peter R; Department of Hematology, Somogy County Móritz Kaposi General Hospital, Kaposvar, Hungary.

المصدر: European journal of haematology [Eur J Haematol] 2024 Aug; Vol. 113 (2), pp. 183-189. Date of Electronic Publication: 2024 Apr 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/mortality , Leukemia, Myeloid, Acute*/diagnosis , Bridged Bicyclo Compounds, Heterocyclic*/administration & dosage , Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic*/adverse effects , Sulfonamides*/administration & dosage , Sulfonamides*/therapeutic use , Sulfonamides*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Azacitidine*/administration & dosage , Azacitidine*/therapeutic use , Azacitidine*/adverse effects, Humans ; Aged ; Male ; Female ; Middle Aged ; Aged, 80 and over ; Treatment Outcome ; Retrospective Studies ; Prognosis

المؤلفون: Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA. Electronic address: GMontalban1@mdanderson.org., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA., Chien K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA., Hammond D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA., Short N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA., Kanagal-Shammana R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, USA., Qiao W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, USA., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, USA., Schneider H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA., Meyer M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA.

المصدر: Leukemia research [Leuk Res] 2024 Jul; Vol. 142, pp. 107518. Date of Electronic Publication: 2024 May 11.

نوع المنشور: Journal Article; Clinical Trial, Phase I

بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE

مواضيع طبية MeSH: fms-Like Tyrosine Kinase 3*/genetics , Mutation* , Myelodysplastic Syndromes*/drug therapy , Myelodysplastic Syndromes*/genetics , Myelodysplastic Syndromes*/mortality , Myelodysplastic Syndromes*/pathology , Benzothiazoles*/administration & dosage , Benzothiazoles*/therapeutic use , Benzothiazoles*/adverse effects , Phenylurea Compounds*/administration & dosage , Phenylurea Compounds*/adverse effects , Phenylurea Compounds*/therapeutic use , Azacitidine*/administration & dosage , Azacitidine*/adverse effects , Azacitidine*/therapeutic use, Humans ; Male ; Aged ; Female ; Middle Aged ; Aged, 80 and over ; Proto-Oncogene Proteins c-cbl/genetics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Myeloproliferative Disorders/drug therapy ; Myeloproliferative Disorders/genetics ; Adult

المؤلفون: Haumschild R; Emory University Hospital Midtown and Winship Cancer Institute, Atlanta, GA, USA., Kennerly-Shah J; The James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Barbarotta L; Smilow Cancer Hospital at Yale New Haven, New Haven, CT, USA., Zeidan AM; Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA.

المصدر: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Jun; Vol. 30 (4), pp. 721-736. Date of Electronic Publication: 2024 Mar 21.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE

مواضيع طبية MeSH: Myelodysplastic Syndromes*/drug therapy , Leukemia, Myeloid, Acute*/drug therapy , Azacitidine*/pharmacokinetics , Azacitidine*/administration & dosage , Azacitidine*/analogs & derivatives , Azacitidine*/therapeutic use , Decitabine*/pharmacokinetics , Decitabine*/administration & dosage, Humans ; Administration, Oral ; Antimetabolites, Antineoplastic/pharmacokinetics ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/therapeutic use ; Uridine/pharmacokinetics ; Uridine/analogs & derivatives ; Uridine/administration & dosage ; Uridine/therapeutic use ; Uridine/pharmacology

المؤلفون: Yin Z; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou City, Guangdong Province, 510515, P.R. China., Yao Z; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou City, Guangdong Province, 510515, P.R. China., Chen D; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou City, Guangdong Province, 510515, P.R. China., Zhang Y; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou City, Guangdong Province, 510515, P.R. China., Weng G; Department of Hematology, Shenzhen Second People's Hospital, Shenzhen, 518035, P.R. China., Du X; Department of Hematology, Shenzhen Second People's Hospital, Shenzhen, 518035, P.R. China., Lin D; Department of Hematology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, 518107, P.R. China., Xiao J; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, P.R. China., Sun Z; Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, 510086, P.R. China., Zhang H; Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, 518036, P.R. China., Liang X; Department of Hematology, The First People Hospital of Chenzhou, Chenzhou, 423000, P.R. China., Guo Z; Department of Hematology, Zhongshan City People's Hospital, Zhongshan, 528403, P.R. China., Zhao W; Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530027, P.R. China., Xuan L; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou City, Guangdong Province, 510515, P.R. China., Jiang X; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou City, Guangdong Province, 510515, P.R. China., Shi P; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou City, Guangdong Province, 510515, P.R. China., Liu Q; Guangdong Provincial Key Laboratory of Digital Medicine and Biomechanics, Guangzhou, 510515, P.R. China., Ping B; Department of Hematology, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou City, Guangdong Province, 510515, P.R. China. nfyypingbaohong66@163.com., Yu G; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou City, Guangdong Province, 510515, P.R. China. yugpp@163.com.

المصدر: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Jul 06; Vol. 150 (7), pp. 336. Date of Electronic Publication: 2024 Jul 06.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Homoharringtonine*/administration & dosage , Homoharringtonine*/therapeutic use , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/pathology , Bridged Bicyclo Compounds, Heterocyclic*/administration & dosage , Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use , Azacitidine*/administration & dosage , Sulfonamides*/administration & dosage , Core Binding Factor Alpha 2 Subunit*/genetics , RUNX1 Translocation Partner 1 Protein*/genetics , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Middle Aged ; Female ; Retrospective Studies ; Aged ; Adult ; Oncogene Proteins, Fusion/genetics ; Young Adult

المؤلفون: DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Olin R; University of California, San Francisco, California, USA., Wang ES; Roswell Park Comprehensive Care Center, Buffalo, New York, USA., Skikne B; University of Kansas Medical Center, Kansas City, Kansas, USA., Rosenthal J; Department of Pediatrics, City of Hope, Duarte, California, USA., Kumar P; Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA., Sumi H; Daiichi Sankyo Co., Tokyo, Japan., Hizukuri Y; Daiichi Sankyo Co., Tokyo, Japan., Hong Y; Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA., Patel P; Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA., Seki T; Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA., Duan T; Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA., Lesegretain A; Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

المصدر: Cancer medicine [Cancer Med] 2024 Jul; Vol. 13 (14), pp. e70028.

نوع المنشور: Journal Article; Clinical Trial, Phase I

بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

مواضيع طبية MeSH: Azacitidine*/administration & dosage , Azacitidine*/adverse effects , Azacitidine*/therapeutic use , Proto-Oncogene Proteins c-mdm2*/antagonists & inhibitors , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Leukemia, Myeloid, Acute*/drug therapy , Maximum Tolerated Dose* , Myelodysplastic Syndromes*/drug therapy, Humans ; Male ; Female ; Aged ; Middle Aged ; Aged, 80 and over ; Adult ; Treatment Outcome ; Carbolines ; Heterocyclic Compounds, 4 or More Rings

المؤلفون: Salamero O; Servei d'Hematologia de l'Hospital Vall d'Hebron i Unitat d'Hematología Experimental del Vall d'Hebron Institut d'Oncología, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: osalamero@vhio.net., Molero A; Servei d'Hematologia de l'Hospital Vall d'Hebron i Unitat d'Hematología Experimental del Vall d'Hebron Institut d'Oncología, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Pérez-Simón JA; Unidad de Hematología y Hematoterapia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), CSIC, Universidad de Sevilla, Seville, Spain., Arnan M; Departament d'Hematología, Institut Català d'Oncología, Hospital Duran i Reynals, Barcelona, Spain., Coll R; Departament d'Hematología, Institut Català d'Oncología, Hospital Dr Josep Trueta, Girona, Spain., Garcia-Avila S; Departament d'Hematología Hospital del Mar, Parc de Salut Mar, Barcelona, Spain., Acuña-Cruz E; Servei d'Hematología i Hematoterapia, Institut d'Investigació Sanitaria La Fe Valencia, Valencia, Spain., Cano I; Servei d'Hematología i Hematoterapia, Institut d'Investigació Sanitaria La Fe Valencia, Valencia, Spain., Somervaille TCP; Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK., Gutierrez S; Oryzon Genomics, Cornellà de Llobregat, Barcelona, Spain., Arévalo MI; Oryzon Genomics, Cornellà de Llobregat, Barcelona, Spain., Xaus J; Oryzon Genomics, Cornellà de Llobregat, Barcelona, Spain., Buesa C; Oryzon Genomics, Cornellà de Llobregat, Barcelona, Spain., Limón A; Oryzon Genomics, Boston, MA, USA., Faller DV; Oryzon Genomics, Boston, MA, USA., Bosch F; Unitat d'Hematología Experimental, Vall d'Hebron Institut d'Oncología, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Montesinos P; Servei d'Hematología i Hematoterapia, Institut d'Investigació Sanitaria La Fe Valencia, Valencia, Spain.

المصدر: The Lancet. Haematology [Lancet Haematol] 2024 Jul; Vol. 11 (7), pp. e487-e498. Date of Electronic Publication: 2024 May 30.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/drug therapy , Azacitidine*/therapeutic use , Azacitidine*/administration & dosage , Azacitidine*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Female ; Aged ; Middle Aged ; Histone Demethylases/antagonists & inhibitors ; Adult ; Dose-Response Relationship, Drug ; Aged, 80 and over ; Cyclohexanes ; Diamines

المؤلفون: Ma C; The First Clinical Medical College of Beijing University of Traditional Chinese Medicine., Lang H; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing., Chen Y; Shenzhen Luohu District Hospital of Traditional Chinese Medicine, Guangdong, China., Yang L; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing., Wang C; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing., Han L; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing., Chen X; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing., Ma W; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing.

المصدر: Anti-cancer drugs [Anticancer Drugs] 2024 Jul 01; Vol. 35 (6), pp. 548-555. Date of Electronic Publication: 2024 Mar 14.

نوع المنشور: Journal Article; Case Reports; Review; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic*/pharmacology , Bridged Bicyclo Compounds, Heterocyclic*/administration & dosage , Azacitidine*/therapeutic use , Azacitidine*/administration & dosage , Sulfonamides*/therapeutic use , Sulfonamides*/administration & dosage , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Tumor Suppressor Protein p53*/genetics , Mutation* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Hematopoietic Stem Cell Transplantation ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/genetics

المؤلفون: Maslah N; INSERM UMR 1131, Universite Paris Cite, IRSL, Paris, France. nabih.maslah@aphp.fr.; APHP, Hopital Saint-Louis, Laboratoire de Biologie Cellulaire, Universite Paris Cite, Paris, France. nabih.maslah@aphp.fr., Rety S; INSERM UMR 1131, Universite Paris Cite, IRSL, Paris, France., Bonnamy M; INSERM UMR 1131, Universite Paris Cite, IRSL, Paris, France., Aguinaga L; APHP, Hopital Saint-Louis, Service d'Hematologie Seniors, Universite Paris Cite, Paris, France., Huynh T; APHP, Hopital Saint-Louis, Service d'Hematologie Seniors, Universite Paris Cite, Paris, France., Parietti V; Université Paris Cité, INSERM/CNRS, US53/UAR2030, Institut de Recherche Saint-Louis, Paris, France., Giraudier S; INSERM UMR 1131, Universite Paris Cite, IRSL, Paris, France.; APHP, Hopital Saint-Louis, Laboratoire de Biologie Cellulaire, Universite Paris Cite, Paris, France., Fenaux P; APHP, Hopital Saint-Louis, Service d'Hematologie Seniors, Universite Paris Cite, Paris, France. pierre.fenaux@aphp.fr., Cassinat B; INSERM UMR 1131, Universite Paris Cite, IRSL, Paris, France.; APHP, Hopital Saint-Louis, Laboratoire de Biologie Cellulaire, Universite Paris Cite, Paris, France.

المصدر: Leukemia [Leukemia] 2024 Jul; Vol. 38 (7), pp. 1630-1633. Date of Electronic Publication: 2024 May 22.

نوع المنشور: Letter; Journal Article

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Myelodysplastic Syndromes*/drug therapy , Myelodysplastic Syndromes*/genetics , Myelodysplastic Syndromes*/pathology , Azacitidine*/pharmacology , Azacitidine*/therapeutic use , Tumor Suppressor Protein p53*/genetics , Mutation* , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/pathology , Niclosamide*/pharmacology , Niclosamide*/therapeutic use, Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology